Market Overview

ISIS Pharma Shares Jump Higher As Piper Jaffray Sees Co.'s Pipeline As 'Most Attractive and Undervalued' In Sector


Piper Jaffray analyst Joshua Schimmer sent ISIS Pharmaceuticals (NASDAQ: ISIS) shares six percent higher Friday morning with some bullish comments on the company.

In the report, Schimmer said he believes ISIS has the “most attractive and undervalued pipeline in biotech.” The analyst argued the undervaluation could be resolved with M&A activity or new management outlook.

Schimmer maintains an Overweight rating and $42 price target on shares of ISIS.

ISIS shares last traded at $26.43.

Latest Ratings for ISIS

Dec 2015Initiates Coverage onOutperform
Nov 2015Initiates Coverage onNeutral
Nov 2015MaintainsEqual-Weight

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Analyst Color News Analyst Ratings


Related Articles (ISIS)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: D.A. Davidson & Co. Reiterates On Zumiez On Encouraging 1Q Upside

Shares Of Aruba Networks Drop In The #PreMarket Despite Record Revenue